Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)

NCT07215273 is registered in ClinicalTrials.gov with Elion Therapeutics, Inc. as lead sponsor.

NCT NCT07215273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07215273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)
Lead sponsor
Elion Therapeutics, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
February 13, 2026
Completion date
December 31, 2026
Enrollment
60 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

invasive mould infection